Budesonide/Formoterol fumarate dihydrate

布地奈德/富马酸福莫特罗

Report date: 2026/05/28 20:00:21

Base Information

Drug NameBudesonide/Formoterol fumarate dihydrate
Drug Alias NameBudesonide/formoterol富马酸福莫特罗布地奈德Budesonide and Formoterol fumarate布地奈德富马酸福莫特罗Formoterol fumarate and Budesonide +[15] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionGlucocorticoid receptor agonistsBeta-2 adrenergic receptor agonists
TargetsBeta-2 adrenergic receptorGlucocorticoid receptor
Therapy Area/IndicationsEmphysemaPulmonary Disease, Chronic ObstructiveLung Diseases, Obstructive +[6] 
Global Approved IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Approved Indications in ChinaPulmonary Disease, Chronic ObstructiveAsthma
Original Approved Country/TerritorySweden
Original Approved Date2000/08/01
Country/TerritoryCzechiaBelgiumBulgaria +[52] 
CombinationsYes Formoterol FumarateBudesonide
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Pharmaceutical Co LtdEmsAstrazeneca Plc +[7] 
Inactive CompaniesZhuhai Resproly Pharmaceutical Technology Co LtdActavis IncPearl Therapeutics Inc +[11] 
Active IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Inactive IndicationsEmphysemaLung Diseases, ObstructivePrecancerous Conditions +[4] 

Other Information

ATC CodeR03AK07
Related LinksWikipediaKEGG